Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Vorinostat (SAHA) and Breast Cancer: An Overview
Anna Wawruszak, Lidia Borkiewicz, Estera Okoń, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4700-4700
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer
Briana Kinnel, Santosh Kumar Singh, Gabriela Oprea‐Ilies, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1320-1320
Open Access | Times Cited: 74
Beyond genetics: Exploring the role of epigenetic alterations in breast cancer
Kirti S. Prabhu, Hana Q. Sadida, Shilpa Kuttikrishnan, et al.
Pathology - Research and Practice (2024) Vol. 254, pp. 155174-155174
Open Access | Times Cited: 15
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Martina Korfei, Poornima Mahavadi, Andreas Guenther
Cells (2022) Vol. 11, Iss. 10, pp. 1626-1626
Open Access | Times Cited: 42
Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
Bi Lian, Xiaosong Chen, Kunwei Shen
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer
Rohan Wedam, Yoshimi Endo Greer, David Wisniewski, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1936-1936
Open Access | Times Cited: 21
Implication of protein post translational modifications in gastric cancer
Houji Song, Mingze Zhang, Chengwang Guo, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 13
Open Access
Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer
Siddhartha Das Pramanik, Amit Kumar Halder, Ushmita Mukherjee, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 30
Double‐strand DNA break repair: molecular mechanisms and therapeutic targets
Jinpeng Tan, Xingyao Sun, Hongling Zhao, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 17
Pan-cancer drivers of metastasis
Ryan Lusby, Engin Demirdizen, Mohammed Inayatullah, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds
Rituraj Chakraborty, Anupam Dutta, Rupak Mukhopadhyay
Clinical & Translational Oncology (2025)
Closed Access
Characterization of the Activities of Vorinostat Against Toxoplasma gondii
Ting Zeng, Chun‐Xue Zhou, Dai-Ang Liu, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 795-795
Open Access
Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives
Ibrahim S. Alalhareth, Saleh M. Alyami, Abdulrhman Alshareef, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 207-207
Open Access
Biological Applications of Acacia Gums (AGs) SME on Breast Cancer Cell Lines
Ahmed A. M. Elnour, Abdurahmani Hamid Nour, Aiman A. Bin Mokaizh, et al.
(2025), pp. 283-306
Closed Access
Histone modification inhibitors: An emerging frontier in thyroid Cancer therapy
Qi Wang, Shu Sun, Guojun Sun, et al.
Cellular Signalling (2025), pp. 111703-111703
Closed Access
Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond
Jianwei Feng, Xinyue Meng
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21
Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects
Jinxiao Ru, Yuxi Wang, Zijia Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115800-115800
Closed Access | Times Cited: 10
Predicting drug response through tumor deconvolution by cancer cell lines
Yu‐Ching Hsu, Yu‐Chiao Chiu, Tzu‐Pin Lu, et al.
Patterns (2024) Vol. 5, Iss. 4, pp. 100949-100949
Open Access | Times Cited: 3
Histone deacetylase inhibitors for leukemia treatment: current status and future directions
Mohammad‐Salar Hosseini, Zohreh Sanaat, Mohammad Amin Akbarzadeh, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 3
Assessment of Pharmacological Interactions between SIRT2 Inhibitor AGK2 and Paclitaxel in Different Molecular Subtypes of Breast Cancer Cells
Anna Wawruszak, Jarogniew J. Łuszczki, Arkadiusz Czerwonka, et al.
Cells (2022) Vol. 11, Iss. 7, pp. 1211-1211
Open Access | Times Cited: 16
RGS10 suppression by DNA methylation is associated with low survival rates in colorectal carcinoma
Feyzanur Çaldıran, Ercan Çaçan
Pathology - Research and Practice (2022) Vol. 236, pp. 154007-154007
Closed Access | Times Cited: 15
γ-Secretase Inhibitor Potentiates the Activity of Suberoylanilide Hydroxamic Acid by Inhibiting Its Ability to Induce Epithelial to Mesenchymal Transition and Stemness via Notch Pathway Activation in Triple-Negative Breast Cancer Cells
Plaboni Sen, Siddhartha Sankar Ghosh
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 10, pp. 1396-1415
Closed Access | Times Cited: 8
Epigenetic and gene therapy in human and veterinary medicine
Eva Bártová
Current Zoology (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2
Epigenetic Modulations in Breast Cancer: An Emerging Paradigm in Therapeutic Implications
Shilpi Sarkar, Dheepika Venkatesh, Thirukumaran Kandasamy, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 8
Open Access | Times Cited: 2
Synthesis, structure activity relationship and biological evaluation of a novel series of quinoline–based benzamide derivatives as anticancer agents and histone deacetylase (HDAC) inhibitors
Negar Omidkhah, Farzin Hadizadeh, Khalil Abnous, et al.
Journal of Molecular Structure (2022) Vol. 1267, pp. 133599-133599
Closed Access | Times Cited: 13
Exploring the synergistic behavior of paclitaxel and vorinostat upon co-loading in albumin nanoparticles for breast cancer management
Ashwin Abhang, Oly Katari, Rohan Ghadi, et al.
Drug Delivery and Translational Research (2023) Vol. 14, Iss. 2, pp. 510-523
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top